FDA Grants Daraxonrasib Access for Pancreatic Cancer After Survival Rose to 13 Months
Updated
Updated · The San Diego Union-Tribune · Jul 6
FDA Grants Daraxonrasib Access for Pancreatic Cancer After Survival Rose to 13 Months
3 articles · Updated · The San Diego Union-Tribune · Jul 6
Summary
Expanded access now lets U.S. patients with previously treated pancreatic cancer seek Daraxonrasib through their oncologists if they cannot join ongoing clinical trials.
Trial data driving the move showed median survival for advanced metastatic disease rising to 13 months from about 6 months with chemotherapy alone.
Nearly two dozen cancer centers are already running trials of the Revolution Medicines drug, which targets RAS-driven tumors and has drawn patients like a 64-year-old Bay Area participant to San Diego for care.
Researchers say the bigger opportunity may be earlier use: PRECEDE, a 65-center pancreatic screening network, has enrolled about 12,000 of a planned 20,000 high-risk people and is finding roughly 75% of its detected cases at stage 1.
Now that a powerful treatment exists, can this same drug be used to stop pancreatic cancer before it even starts?
With a breakthrough pill available, are personalized cancer vaccines the next major frontier in fighting this disease?
Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer: FDA Fast-Tracks Access Amid Unprecedented Hope and Challenges
Overview
Pancreatic cancer is one of the deadliest cancers, with over 50,000 Americans dying each year and a five-year survival rate of just 3% for those with advanced disease. Because there are few effective treatments and a great unmet medical need, the FDA acted quickly on daraxonrasib, an investigational drug, by granting it expedited designations and launching an Expanded Access Program. This swift response aims to give hope to patients who have limited options, showing how urgent the situation is and how new therapies like daraxonrasib could make a real difference for those facing this challenging cancer.